Form 4: Acurx Pharmaceuticals Director Jack H. Dean Acquires Shares and Warrants in Direct Offering

Director Jack H. Dean acquired shares and warrants of Acurx Pharmaceuticals through a registered direct offering and concurrent private placement.

Summary

• On January 6, 2025, Jack H. Dean, a director of Acurx Pharmaceuticals, acquired 9,852 shares of common stock at a price of $1.015 per share through a registered direct offering.
• Dean also acquired warrants for 9,852 shares of common stock at a price of $0 in a concurrent private placement.
• Following these transactions, Dean directly owns 21,776 shares of common stock and indirectly owns 5,770 shares through the Dean Family Trust, for which he serves as trustee.
• He also directly owns 9,852 warrants for common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard insider trading activity. The director's purchase could be seen as a positive signal, but it's a routine transaction.

Positives

• A director's investment in the company may signal confidence in its future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder confidence.

Key Dates